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Abstract
Acute respiratory failure is a frequent complication in elderly patients especially if suffering from chronic cardio-pulmonary
diseases. Non-invasive mechanical ventilation constitutes a successful therapeutic tool in the elderly as, like in younger
patients, it is able to prevent endotracheal intubation in a wide range of acute conditions; moreover, this ventilator
technique is largely applied in the elderly in whom invasive mechanical ventilation is considered not appropriated.
Furthermore, the integration of new technological devices, ethical issues and environment of treatment are still largely
debated in the treatment of acute respiratory failure in the elderly.
This review aims at reporting and critically analyzing the peculiarities in the management of acute respiratory failure in
elderly people, the role of noninvasive mechanical ventilation, the potential advantages of applying alternative or
integrated therapeutic tools (i.e. high-flow nasal cannula oxygen therapy, non-invasive and invasive cough assist devices
and low-flow carbon-dioxide extracorporeal systems), drawbacks in physician’s communication and “end of life” decisions.
As several areas of this topic are not supported by evidence-based data, this report takes in account also “real-life” data as
well as author’s experience.
The choice of the setting and of the timing of non-invasive mechanical ventilation in elderly people with advanced
cardiopulmonary disease should be carefully evaluated together with the chance of using integrated or alternative
supportive devices. Last but not least, economic and ethical issues may often challenges the behavior of the physicians
towards elderly people who are hospitalized for acute respiratory failure at the end stage of their cardiopulmonary and
neoplastic diseases.
Keywords: Acute respiratory failure, Non-invasive mechanical ventilation, Endotracheal intubation, End-of-life, High-flow
nasal cannula, CO2-removal, Bronchoscopy, Elderly patient
Background
Thanks to the modern pharmacological and non-
pharmacological approach (i.e., long-term oxygen ther-
apy and home mechanical ventilation) pulmonologists
are able to prolong the survival of patients with chronic
respiratory diseases till the very advances stages of their
natural history [1]. However, the increase in the survival
rate is not always associated with a satisfactory quality of
life since an impaired lung function is often associated
with a limitation in his/her daily activities living and
with discomfort (i.e., dyspnea, weakness, depressive
symptoms) [2, 3]. As a matter of the fact, prolonging
survival is not always a desirable goal to achieve for both
the physician and the patient according to the modern
vision of patient-centred management of diseases [4].
Conversely, palliation of symptoms and shared “end-of-
life” decisions are the main target of the care in order to
keep a human dignity in the transition to the death in
patients with advanced chronic respiratory diseases [5].
On the other hand, severely disabled patients with “end-
stage” cardio-pulmonary disease may agree to undergo
life-support devices (i.e. mechanical ventilation) in Hos-
pital to overcome an episode of acute decompensation
even if the impairment in their quality of life at home
may still progress depending on the severity of their
underlying condition. Moreover, undue “nihilism” about
outcomes of invasive mechanical ventilation (IMV) in
conditions such as chronic obstructive lung disease
(COPD), is common and of concern, as patients may be
swayed by inaccurate inferences about the likely out-
come, should support be provided. Because decisions on
whether to admit patients with COPD or asthma toCorrespondence: raffaele_scala@hotmail.com
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intensive care setting for endotracheal intubation (ETI)
depend on clinicians’ prognoses, the CAOS study [6]
highlighted that in the some patients who might otherwise
survive are probably being denied admission because of
unwarranted prognostic pessimism of physicians. Within
this context, the management of patients at the “end of
stage” of their underlying cardiopulmonary disease who
are hospitalised for an episode of acute respiratory failure
(ARF) may raise ethical dilemma concerning the choice of
the level of the “escalating therapy” that could be poten-
tially offered ranging from the medical and oxygen-
therapy till IMV [4].
With the progressive extension of the natural history of
many chronic pulmonary and extra-pulmonary diseases,
inevitably the incidence rate of elderly patients admitted
in the hospital for ARF is continuously increasing.
Accordingly, the risk of developing a boot of ARF
increases with the age and this phenomenon occurs
mainly in elderly people with underlying chronic cardio-
pulmonary disorders, immunosoppressed conditions, solid
and hematologic malignancies and coexisting multiple
extra-pulmonary comorbidities [7]. Triggering causes of
ARF in advanced aged patients are especially acute heart
decompensation, severe community acquired pneumonia,
acute exacerbations of COPD, drug-induced lung injury.
In a subset of elderly patients the deterioration of lung
function may occur without any evidence of a superim-
posed condition and could be considered as an inevitably
progression of the natural history of the underlying
disease [7].
Main text
Therapeutic options for acute respiratory failure in the
elderly
Similarly to the adult population, the first support for
the treatment of ARF in the elderly is represented by the
delivery of conventional oxygen therapy via a facemask
or nasal cannula to “buy the time” for the etiologic ther-
apy to reverse the cause of the acute decompensation of
the respiratory system [8, 9]. Once physicians realize
that only oxygen-therapy is not enough to properly and
quickly correct the impaired lung gas exchange and to
reduce the burden of respiratory distress, non-invasive
ventilation (NIV) becomes the following option whose
aim is to avoid the need for IMV, as well as to prevent
its life-threatening complications [10]. Even though in
the last two decades NIV has dramatically changed the
epidemiology of mechanical ventilation in an expanding
number of acute clinical scenarios, the chance of success
with this ventilatory technique is variable and strongly
depends on several variables, such as team’s experience,
patient-ventilator synchrony, air leaks, adequate equip-
ment and environment, patho-physiology pattern, timing
and severity of ARF [10]. Above all, the adherence to the
scheduled ventilatory treatment is the crucial “ingredi-
ent” for successfully adapting, carrying on and weaning
the patient off from the ventilator [10–12]. As a matter
of the fact, when NIV is or become a unviable thera-
peutic option, the subsequent mandatory option is ETI
and IMV delivered in high-intensity monitored hospital
setting. Furthermore, refractory hypoxemia during IMV
in severe acute respiratory distress syndrome (ARDS)
may require the implementation of “artificial lung” by
means of extra-corporeal membrane oxygenation
(ECMO) [13]. At this stage of ARF, multiple organ dys-
function is likely to occur with the need for extra-
pulmonary support, such as renal replacement therapy.
In case of refusal of life-support devices, palliation care
and terminal sedation is an “end-of-life” therapeutic op-
tion which may be considered by both the physician and
the patient [4]. New therapeutic options could be ap-
plied as either alternative or integrative supportive strat-
egy to NIV, such as high-flow nasal cannula (HFNC) [9],
non-invasive cough assist devices -such as mechanical
insufflator-exsufflator (MI-E) [14], high frequency chest
wall oscillation (HFCWO) [15], flexible bronchoscopy
(FOB) [16], extracorporeal CO2 removal (ECCO2R) [17]
both in patients who are failing NIV and in those who
are at risk of developing extubation failure.
Mechanical ventilation in the elderly
While the application of the conservative therapeutic ap-
proach based on the solely administration of drugs and
oxygen within the context of non-intensive care setting
(i.e., ward and other un-monitored areas) is not dissimi-
lar in the elderly than in adults, the choice of adminis-
tering mechanical ventilation in higher intensity of care
environment [i.e., general Intensive Care Units (ICU)
and Respiratory Intensive Care Units (RICU)] in octoge-
narians is controversial [7]. In fact, despite the prognosis
of patients undergoing mechanical ventilation has not
been shown to be different in the elderly than in the
younger population, the former usually receive less in-
tensive and expensive care than the latter having the
same degree of clinical-physiological derangement. This
is particularly evident in the elderly with chronic cardio-
pulmonary diseases hospitalized for an episode of ARF
for whom the denial of ICU/RICU admission is often de-
termined by an unjustified pessimistic prognostic per-
spective shown by physicians [6]. The still poorly
defined border between “curative”, “palliative” and “end-
of-life” treatment in patients with “end-stage” lung dis-
eases makes more complex this clinical scenario [4, 5,
18]. In patients with advanced respiratory disease, indi-
vidual Hospital units vary greatly in regard to selection
based on age. Even if the “age-based” restriction access
to higher level of care is not justified by the existing
data, in some institutions the label of “do-not-intubate”
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order (DNI) may be applied to octogenarians with
chronic advanced respiratory disease [4]. In the Fig. 1
the therapeutic options available in the elderly with ARF
are depicted.
The role of non-invasive ventilation in the elderly
Rationale
NIV is the first-choice ventilatory technique in some
diseases (COPD, cardiogenic pulmonary edema, immuno-
suppression of different origin, neuromuscular disease
without severe bulbar impairment, obesity hypoventilation
syndrome and chest wall deformity) which have an high
prevalence in the elderly [10]. The advantage of NIV is to
offer the same physiological effects of IMV delivered via
ETI (i.e., unloading respiratory muscles, improvement gas
exchange, augment alveolar ventilation) avoiding the risks
correlated with the use of an artificial airway (endotracheal
tube, tracheostomy cannula), such as ventilator-associated
pneumonia, whose incidence rate is especially high in the
elderly [19]. Since most patients receiving NIV are man-
aged without sedation, early weaning off from the ventila-
tor is facilitated and sedative drug-related complications
are avoided. Keeping in mind the drawbacks of NIV (i.e.,
lack of airway protection, need of patient’s cooperation,
preserved cough reflex), the early use of this ventilatory
technique in addition to the oxygen and medical therapy
for the management of ARF is able to significantly reduce
the rate of intubation, the length of hospital stay and the
hospital mortality rate especially in acidotic hypercapnic
patients, included those in their elderly age [10]. In
addition to that, it has been documented the effectiveness
of NIV as “ceiling ventilatory treatment” in DNI elderly
patients with chronic cardio-respiratory diseases [19, 20].
Recent data also demonstrated the usefulness of NIV as
palliation in different clinical situations, such as patients
with “end-stage” solid tumors and ARF, many of them be-
ing over seventy-five year’s old [4, 21].
Although NIV could be considered a proper thera-
peutic tool in elderly population with ARF, some pecu-
liar issues should be considered such as environment,
selection of patients, palliative care and “end-of-life”
decisions.
Environment
The most suitable hospital setting where to start NIV in
the elderly should have expert staff in an adequate num-
ber according to the severity of patient’s conditions for
24/24 cover, multi-parametric monitoring, prompt avail-
ability to invasive ventilation, reasonable costs, a struc-
tured discharge plan, consideration of “end-of-life”
choices (Fig. 2) [10, 22, 23]. ICU fits all these criteria ex-
pect for the costs and, therefore, there is an imbalance
between the ICU beds and the number of patients re-
quiring NIV. This is particularly true for elderly patients.
Starting NIV outside ICU has the advantage of treating
less severe patients with the similar rate of success but at
lower costs than in ICU [22] avoiding a potential distres-
sing experience. However, the low level of care provided
in some environment might increase the risk that deteri-
oration of patients receiving NIV will not be promptly rec-
ognized and treated [24]. RICU represents a balanced
setting where there are expertise in NIV, cost-
effectiveness, knowledge of the history of chronic respira-
tory patients, awareness of end-of-life issues [25–27].
The term RICU refers to specialized units for patients
who require an “intermediate” level of care between the
ICU and the ward where non-invasive monitoring and
assisted ventilation techniques are mainly, even if not
exclusively, applied. RICU acts as “step-down unit” for
stabilized patients transferred from ICU (i.e., weaning
and decannulation) and as “step-up unit” for cases not
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Fig. 1 Therapeutic options in elderly with acute respiratory failure
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responding to medical therapy in emergency depart-
ments or wards [25, 27]. As a matter of the fact, the
availability of an “intermediate-respiratory” setting to
manage “mono-organ” decompensations avoids the dan-
gerous “under-assistance” in low-care environment (i.e.,
ward) and the uselessly “over-assistance” in high-care
environment (i.e., ICU) [25]. This is why RICUs may
provide a specialized quality of care for the clinical gov-
ernance of ARF with health resources optimization (i.e.,
reduced nurse-to-patient ratio). In fact, compared to the
direct and indirect high costs required by traditional
ICUs, RICUs advantages are linked to the lower nursing
staff requirements and to the improved utilization of the
ICU resources (i.e. patients with severe multi-organ fail-
ure) [25]. Conversely, discharge from the ICU to the
RICU becomes possible for patients who have recovered
from the acute phase of critical illness but still need in-
tensive nursing or physiotherapy before being weaned
from the ventilator [25]. This concept is particularly true
for elderly patients with advanced chronic cardio-
pulmonary diseases who are often refused to be admit-
ted to ICU because too old and too ill. Besides the eco-
nomical factors, there are other advantages which favor
the RICU for the management of these patients. More
privacy for the patient and easier family’s access which
characterize the RICUs may contribute to the “healing”
process and facilitate discharge, especially for those pa-
tients requiring long-term oxygen therapy and/or mech-
anical ventilation at home [25]. It should be empathized
that the term RICU as “intermediate level of care” has
not the same “conceptual meaning” among the different
countries and, therefore, a large heterogeneity emerges
also within the same country. Basically, the main differ-
ences are due to the following factors: human resources
(i.e. nurse to patient ratio; availability of physicians 24 h
a day; presence or not of respiratory therapists);
organization model (i.e. independent RICU vs RICU
inside ICU vs RICU inside a ward); specialist vocation
(i.e. respiratory vs medical intermediate care unit); func-
tional mission in the Hospital (i.e. step-down unit vs
step-up unit vs rehabilitative unit vs weaning unit); prac-
tical skills (i.e. management of airway with provision of
ETI, extra-pulmonary support) [27].
The issue of where to start NIV is still debated for
the heterogeneity of settings capable of delivering
NIV even within the same hospital depending on the
team’s expertise, the availability of prompt ETI and
the existence/lack of well defined step-down and/or
step-up pathways [22, 23].
Choice of where starting NIV is based on patient’s
need for monitoring, unit’s monitoring capabilities, staff
experience, and time-response to NIV [10, 22, 23]. Pa-
tients with ARF poorly responsive to NIV, such as pneu-
monia, ARDS, and asthma, should be treated in ICU,
where immediate ETI is available. One exception is
when NIV is applied in ‘do-not-intubate’/‘do-not-resus-
citate’(DNI)/DNR) context, to palliate symptoms [4, 5].
Fast-responding diseases (ie. acute cardiogenic pulmon-
ary oedema) may be appropriately ventilated in short-
stay enviroment, such as pre-hospital transport and
emergency department [10, 22, 23].
Selection of patients
Concerning this issue some points should be considered
when starting NIV in the elderly patients. Figure 3
shows the aims of NIV in the elderly within different
clinical scenarios of ARF.
Firstly, clinician ought to have clear in mind the goals
to achieve when NIV is applied [4, 5, 8, 28]: 1) to pre-
vent the occurrence of impending (but not established)
ARF or post-extubation failure, (2) to prevent further
clinical-physiological deterioration and the need for ETI
when ARF is already established but ventilatory support
is not mandatory; 3) as alternative to IMV when ventila-
tory support is mandatory quoad vitam or as a tool for
facilitating the weaning from IMV; 4) as a palliative care
in DNI/DNR patients with “end-stage” chronic respira-
tory or neoplastic diseases. This point strongly influ-
ences when and where to start NIV, as well as what to
do in case of treatment failure. Concerning the timing,
NIV should be started early because a delay may permit
further deterioration and increase the likelihood of fail-
ure. However, there is no point in starting NIV too early
in patients with mild signs of ARF especially in hyper-
capnic patients [28].
Secondly, clinician has to carefully identify the type of
disease in acute decompensation to be treated at first
with NIV [10]. A first distinction should be made be-
tween hypercapnic ARF mostly occurring in patients
with preexistent chronic respiratory disorders (i.e.,
COPD, chest wall deformities, neuro-myopathies) and
Fig. 2 Characteristics of the different settings where non-invasive
ventilation (NIV) may be applied. Green, yellow, red indicates respectively
a highly favorable, favorable, unfavorable issue for the different enviro-
ment. ICU: Intensive Care Unit, RICU: Respiratory Intensive Care Unit, ED:
Emergency Department, ETI: endotracheal intubation, EOL: end-of-life
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hypoxemic or “de novo” ARF occurring in patients with-
out preexistent cardiorespiratory diseases (i.e., ARDS),
being the former more responsive to NIV than the latter.
An important exception are patients with neuromuscular
diseases, particularly progressive conditions such as
amyotrophic lateral sclerosis (ALS), that leads to pump
failure with progressive hypercapnia; this condition
could be effectively managed with NIV provided that
bulbar function is preserved [29].
Thirdly, as in any medical interventions, care should
be taken in excluding from a NIV trial patients with
contraindications. Some of these conditions, such as
cardio-respiratory arrest, require immediate intubation
and invasive ventilation. However, other classical contra-
indications are derived from exclusion criteria of RCTs
and, consequently, it’s more correct to state that NIV is
not proven in these circumstances [10, 22]. For instance,
NIV is considered contraindicated in encephalopathy
based on the concern that it would increase the risk of
pulmonary aspiration and reduce patient’s cooperation.
This is not true at least for altered level of consciousness
due to hypercapnic encephalopathy which may be
“safely” reversible with NIV [30]. In a prospective case–
control study of patients with COPD exacerbations and
moderate-to-severe hypercapnic encephalopathy, most
of them in their elderly age, the use of NIV versus IMV
was associated with similar short and long-term survival
and fewer nosocomial infections [31]. Another example
is the feasibility of NIV to successfully treat episodes of
ARF occurring in patients having secretion’s retention
and/or depressed cough thanks to an integrated strategy
aiming at improving airways clearance [14, 32]. While
NIV is well tolerated when the sensorium is severely de-
pressed, agitation may ensue when the patient is awak-
ing and prevent him/her to keep on ventilation. A status
of agitation and/or delirium frequently occurs in the eld-
erly with ARF. Strategies based on the cautious use of
low-doses of sedatives (i.e. opioids) provided in a high
level of care setting could be attempted in mildly
agitated patients during NIV [33]. In expert hands, pa-
tient comfort and patient-ventilator synchrony may be
improved by “a safe” sedation even in case of intolerance
[32]. Although this strategy is feasible, the risk of overse-
dation and need for intubation should be carefully con-
sidered [10, 34].
The use of predictive factors may be useful in the
selection-making process even though those with a
greater predictive value (i.e., clinical-physiological pa-
rameters after a trial of NIV) are not available before
starting ventilation. Nevertheless, the finding at baseline
of severe acidosis (i.e. pH < 7,25), remarked “de novo”
hypoxemia (i.e. PaO2/FiO2 < 200) and non-pulmonary
organ failures are associated with a likelihood of NIV
failure [10, 34, 35]. Being considered NIV as the applica-
tion of “ars medica”, there is not a “magic formula” that
precisely will “broadcast” the future of patients started
to this “miracle machine” [22]. This is particularly true
for elderly subjects with ARF. As a matter of the fact, at
the end, whether clinician should attempt NIV is based
on individual circumstances. For instance, if IMV is not
considered appropriate (i.e., DNI/DNR status), a trial of
NIV could be considered. Although there are few
contra-indications to NIV in patients deemed not for in-
tubation, the likelihood of a favorable outcome should
be discussed with the patients and their families. The
reason is why NIV could be an “intrusive therapy”, and if
there is little chance of a good outcome initiating NIV
may increase distress and alternative palliation strategy
would be more appropriate. Table 1 summarizes the
likely outcome of NIV for the main clinical indications
in the elderly with ARF.
Integrated strategy to avoid NIV failure
NIV failure
Even in expert hands, NIV failure may occur in 5–60%
of the treated cases, depending on numerous factors, in-
cluded the severity of ARF, the expertise of the team,






















































Fig. 3 Reasons for applying non-invasive ventilation in elderly at different stages of acute respiratory failure
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[34]. The early identification of NIV failure is of pivotal
importance as the unduly delay of IMV may be associ-
ated with an increased mortality. According to the tim-
ing of occurrence, NIV failure may be distinguished in:
1) immediate failure (within minutes to <1 h), due to
weak cough reflex, excessive secretions, hypercapnic en-
cephalopathy syndrome, intolerance, agitation, and
patient-ventilator asynchrony; 2) early failure (from 1 to
48 h), due to poor arterial blood gas and an the inability
to promptly correct them, increased severity of illness,
and the persistence of a high respiratory rate with re-
spiratory muscle’s distress; and 3) late failure (after
48 h), which can occur after an initial favorable response
to NIV and may be related to sleep disturbance and se-
vere comorbidities [34, 35].
Integrated strategy
The integration of NIV with other less invasive supports
(e.g. HFNC, mechanical cough assistance devices, FOB
with toilette of abundant secretion, low-flow CO2-re-
moval systems) could reduce the rate of NIV failure and
may be especially feasible in the elderly in which IMV is
not desirable [36–46]. Figure 4 details the different strat-
egies of NIV integrated with other procedures according
to various clinical situations.
The conventional oxygen-therapy to treat hypoxemic
patients shows several drawbacks [9] such as the impre-
cise estimation of the delivered fraction of inspired O2
(FiO2) depending on the patient’s breathing pattern, the
CO2-rebreathing with “reservoir” devices, the subject’s
discomfort due to mask poor tolerance and interference
with eating, drinking, speaking, insufficient heating and
humidification of the administered oxygen, and last but
not least the mismatch between the limited amount of
the deliverable oxygen flow and the high patient’s in-
spiratory request. Furthermore, conventional oxygen
therapy is unable of unloading respiratory muscles and
may cause a rise in PaCO2 level with a contextual drop
in pH leading to the need for mechanical ventilation es-
pecially in patients with acute on-chronic hypercapnic
respiratory failure. HFNC is a new system that is able to
deliver up to 100% heated and humidified oxygen at a
maximum flow of 60 L/min of gas via a nasal cannula
[9]. Thanks to its technological peculiarity, HFNC has
several physiological advantages over conventional oxy-
gen therapy: 1) capability of administering precise values
of FiO2 ranging from 21 to 100%; 2) efficient clearance of
CO2 correlated with high flushing of pharyngeal dead; 3)
good efficiency in humidifying and heating the delivered
oxygen-air mixture with an improved capacity of removing
secretions; 4) great patient’s comfort towards the treatment
which does not interfere with eating, drinking, speaking; 5)
adequate matching between the flow rate provided by the
device and the patient’s inspiratory demand; 6) “stenting ef-
fect” on upper airways and alveolar recruitment due to the
generation of flow-dependent low PEEP levels (up to a me-
dian of 7.4 cmH2O at 60 L/min) [9]. An increasing amount
of clinical data, even if mostly uncontrolled, are accumulat-
ing about the feasibility, efficacy and tolerance of HFNC in
hypoxemic ARF of different etiology with the aims of redu-
cing the escalating ventilatory therapy (i.e., NIV and IMV),
in “DNI patients” as alternative to NIV, in “end-stage”
chronic cardio-pulmonary diseases with ARF, in post-
cardiac surgery patients as prophylactic support to reduce
the need of mechanical ventilation, during FOB in high-risk
ARF patients. A large of these clinical applications concerns
elderly patients with ARF especially those with “DNI-sta-
tus” who do not cope with NIV [36]. Recent reviews of the
literature report the current knowledge about HFNC, from
its mechanisms of action to its effects on outcomes in dif-
ferent clinical situations [37, 38].
Another important drawback for the successful use of
NIV in patients with a depress cough reflex is the ineffi-
cacy to spontaneously clear airways from an excessive
burden of respiratory secretions, this is essentially due to
the kinds of interfaces used to deliver NIV, which do not
allow direct access into the airways. Consequently, the
inability to spontaneously remove respiratory secretions
has been considered a contraindication to start NIV in
ARF, especially in patients with altered level of con-
sciousness associated with depressed cough [7, 8, 10, 11,
34]. Non-invasive and “mini-invasive” integrated strat-
egies may be attempted to avoid NIV failure due to ac-
cumulated secretions into the airways tree.
In ARF of neuromuscular origin in patients with pre-
served bulbar function a large body of evidence support
Table 1 Likelihood of success of NIV in elderly patients
according to the different types of ARF
Clinical condition with Acute
Respiratory Failure
Avoidance of intubation Reduction
of Mortality
COPD exacerbations +++
Cardiogenic pulmonary edema +++
Immuno-compromised status +++
Obesity-hypoventilation +++
Chest wall deformities +++
Weaning/Extubation in COPD ++−
Mild-moderate Encephalopathy ++−
Neuromuscular diseasesa ++−
Community Acquired Pneumonia +−−
Mild ARDS +−−
Agitation/Deliriumb +−−
Interstitial fibrotic lung diseases —
Multi-organ failure/Comorbidities —
a with cough augmentation techniques
b with low doses of sedatives
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the combined use of NIV plus MI-E for the management
of secretions in patients with a severely impaired cough
efficiency [14, 34]. However, very recently, a RCT has
shown that the “breath-stacking” technique using a lung
volume recruitment bag turns out to be as efficient as
the MI-E technique in enhancing secretion clearance in
ALS patients with ARF [39]. So far, the “breath-stacking”
technique could be considered as a low-cost, first-line
intervention for volume recruitment and cough augmen-
tation in patients with ALS who meet the criteria for
intervention with NIV.
Conversely, few published data suggested that some
non-invasive physiotherapeutic techniques may improve
mucous clearance in chronic lung diseases in acute exac-
erbations managed with NIV. Some papers demon-
strated that acute-on-chronic respiratory patients with
bronchial hypersecretions of different etiology showed
improvement of PaO2 and PaCO2 values when NIV was
associated with HFCWO applications [40, 41]. However,
a systematic review has not demonstrated the usefulness
of HFCWO in improving the clinical outcomes of hospi-
talized COPD patients in acute exacerbations in com-
parison with the usual medical care; consequently, the
role of this technique in these patients remains still con-
troversial [42]. This is true also for patients with neuro-
muscular diseases for whom the available data do not
support the routine application of HFCWO.
Concerning the role of “therapeutic” use of FOB dur-
ing NIV [34, 43, 44], in a matched case–control study
Scala et al. [16] compared 15 acutely decompensated
COPD patients with copious secretion retention and hy-
percapnic encephalopathy due to pneumonia undergoing
early FBO plus BAL during NIV in an expert RICU with
15 controls receiving IMV in the ICU. Two hours of
NIV plus FBO significantly improved blood gases,
sensorium and cough efficiency without major complica-
tions (cardiovascular events, emergent ETI, pneumo-
thorax). Improvement in PaCO2 and pH, as well as
hospital mortality, and durations of hospitalisation and
ventilation were similar in NIV vs IMV groups. NIV sig-
nificantly reduced serious infectious complications com-
pared with IMV, as well as the need for tracheostomy.
Even if this NIV strategy may be a successful alternative
to IMV to manage selected COPD patients within expert
units, larger RCTs are necessary to confirm this prelim-
inary result.
ECCO2R, which developed from the traditional ECMO
[17], has been recently proposed as an alternative or an
integrated therapeutic option in patients with acute hy-
percapnic acidotic respiratory failure who are “non-re-
sponder” to a NIV trial [45, 46]. While ECMO is a “total
extra-corporeal support” which is able to oxygenate se-
verely hypoxemic patients and remove up to 50% of the
total body CO2 production, ECCO2R works as a “partial
extracorporeal support” capable of removing lower
amount of CO2 without substantial effects on the oxy-
genation. Being less invasive than ECMO (lower blood
flows, lower diameter cannulation, lower doses of hep-
arin), ECCO2R is associated with fewer severe complica-
tions [17]. As well as in ARDS patients and in severely
chronically ill patients as bridge to transplant, ECCO2R
has been recently applied in severe hypercapnic respira-
tory failure due to COPD exacerbations, mostly occur-
ring in elderly subjects [17, 46]. In a recent matched
study with historical controls the addition of ECCO2R to
NIV in 25 COPD elderly patients with severe acidotic
exacerbation at risk of NIV failure was associated with a
significant improvement in blood gases and respiratory
rate with a non-significant reduction in ETI rate as com-
pared to an matched control group of 21 patients
NIV + HFCWO
Fig. 4 Flow-chart depicting the potential integrated respiratory therapies in adjunct to NIV in case of risk of failure in cases of elderly patients
with DNI status. ARF: acute respiratory failure, ECCO2R: extracorporeal CO2 removal, FOB: flexible bronchoscopy, HES: hypercapnic encephalopathy
syndrome, HFCWO: high-frequency chest wall oscillation, HFNC: high-flow nasal cannula, NIV: non-invasive ventilation
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receiving only non-invasive ventilator support [47].
However, 13/25 patients (52%) submitted to ECCO2R
plus NIV experienced adverse events related to extracor-
poreal CO2 removal. Bleeding episodes were observed in
three patients, and one patient experienced vein perfor-
ation. Malfunctioning of the system caused all other ad-
verse events. The Authors concluded that even if a short
treatment with ECCO2R may be efficacy in quickly and
persistently removing the excess of CO2 in severe hyper-
capnic acutely decompensated COPD patients who are
going to fail with NIV assistance, the widespread use of
this approach, especially in DNI elderly patients, could
not be recommended due to the potential serious com-
plications and the lack of robust proven clinical evi-
dence. A subsequent systematic review analyzing the
effectiveness and safety of ECCO2R to avoid intubation
or reduce length of invasive ventilation in hypercapnic
respiratory failure due to COPD exacerbations highlights
that this technique is still experimental and no random-
ized trial is available. Therefore, higher-quality studies
are required to better elucidate the risk-benefit balance
of ECCO2R [46]. This is particularly true in fragile eld-
erly patients who are at higher risks of hemorrhagic
complications.
NIV and palliation
In case of use of NIV in elderly patients with “DNI-sta-
tus” having poorly responsive diseases (e.g. “hypoxemia
de novo” or interstitial lung diseases) physicians must
carefully evaluate the relationship between its potential
favorable clinical effects and its risk of uselessly pro-
longation of a discomfort procedure [4, 5, 19, 26].
The “palliative use” of NIV in patients who have de-
cided to forego ETI and in those with “end-stage” re-
spiratory disease is still controversial according to the
available published data [4, 5, 19]. Some Authors have
suggested the palliative use of NIV in this scenario to al-
leviate respiratory distress and/or to allow the communi-
cation and/or to provide additional time to finalize
personal affairs and to come to the acceptance of death
[48]. Conversely, other Authors considered this use in-
appropriate as NIV is still a form of life support even if
delivered non-invasively by a mask that may cause itself
discomfort and may prolong uselessly the dying process
while diverting critical care resources away from other
patients more likely to survive [49]. The more controver-
sial point is whether the benefit of NIV in palliate dys-
pnea may be outweighed by the discomfort and the
limited communication induced by a tight-fitting face
mask. In addition to that the physician should not forget
to consider and to let the patient/family known the
other possible complications of NIV, such as gastro-
distension, eye irritation, pneumothorax, agitation,
patient-ventilator asynchrony, hemodynamic instability
that may further deteriorate the poor quality of life of
DNI patients [4, 50, 51].
Recently, a Task Force on the “Palliation Use of NIV”
of the Society of Critical Care Medicine [5] suggested to
classify the use of NIV for patients with ARF into three
categories: 1) NIV as life support with no preset limita-
tions on life-sustaining treatments; 2) NIV as life support
when patients and families have decided to forego ETI;
3) NIV as a palliative measure when patients and fam-
ilies have chosen to forego all life support, receiving only
comfort measures. This Task Force suggests an approach
to use of NIV for patients and families who choose to
forego ETI. NIV should be applied after careful discus-
sion of the goals of care, with explicit parameters for
likelihood of success and failure, by experienced
personnel, and in appropriate healthcare settings. It’s im-
portant to acknowledge that individual patients may
transition from one to another category as the goals of
the care or the risk/benefit balance of NIV may dynam-
ically changed [4, 5].
The goals and the time for discontinuation of NIV are
similar for the category of patients who decline ETI and
IMV with the difference that NIV will be withdrawn and
comfort measure only intensified if NIV is not successful
and/or not tolerated any longer. Conversely from the
first two categories of candidates for NIV, patients be-
longing to the third category, such as those at the “end-
stage” of a chronically progressive diseases (i.e., COPD,
neuromuscular disorders, chronic heart failure) or those
with terminal malignancy, most of them over 70 year
old, do not want any form of life-prolonging therapy as
their baseline quality of life is found unacceptable des-
pite a maximal out-patient therapy. Patients in this cat-
egory should not be encouraged to tolerate the NIV-
associated discomfort because the goal of the chosen
therapy is only the palliation of the symptoms and not
the improvement of physiological parameters [52]. In
this scenario there is no sense in providing NIV to pa-
tients who are unable to communicate (i.e., decreased
level of consciousness) as they could not feel the poten-
tial impact of NIV on their symptoms [4, 5]. This pallia-
tive use of NIV may also allow comfort measure only for
patients to be transferred home in order to spend the
end of his life in his own bed [4, 48, 49]. This scenario is
often referred to elderly patients.
Another unexplored question is whether NIV is more
effective than pharmacological therapies, such as opiates,
in palliating symptoms. It’s a crucial point that the pa-
tient can and must keep the control over the decision to
carry on NIV. If discomfort related to the use of the
mask exceed the benefit the patient may simply choose
to discontinue NIV and his/her comfort should be
achieved with drugs. The use of anticipated doses of opi-
ates before withdrawing NIV at the end of life may be an
Scala BMC Pulmonary Medicine  (2016) 16:150 Page 8 of 10
option to achieve the higher level of patient comfort,
similarly to what was already reported with invasive
mechanical ventilation [53]. The transition from mech-
anical support to an oxygen mask looks much simpler
both ethically and technically with NIV than with inva-
sive ventilation.
A very appealing goal of NIV in such kind of patients
is to achieve a good control of the dyspnea in addition
to the traditional pharmacological therapy. Results of a
recent multicenter randomized controlled study [21]
performed in advanced solid cancer patients showed that
compared to the only oxygen and medical therapy the
adjunct of NIV may reduce the amount of the needed
doses of opiates and therefore their side effects, such as
the depressed level of sensorium. Thus may mean a bet-
ter capability of communication for the patient at the
end of his life with a good control of symptoms.
Conclusions
Treatment of ARF in the elderly should take into ac-
count the technical and scientific aspects of ventilatory
and non-ventilatory supporting devices as well as ethical
and economic issues that have to be contextualized de-
pending on the type of disease, the degree of patient in-
formation, the achievement of shared choices, local
health resources, team expertise in mechanical ventila-
tion. NIV is the ventilatory support of first choice in the
elderly when physician considers the correct selection of
the case and the appropriate choice of the setting and of
the timing of application. NIV failure should be managed
carefully depending on the will of the patients to
undergo either to the escalating therapy or the palliative
care.
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